Background: Vaccine regulation in China meets World Health Organization standards, but China's vaccine industry and immunization program have some characteristics that differ from other countries. We described the history, classification, supply and prices of vaccines available and used in China, compared with high-and middle-incomes countries to illustrate the development of Chinese vaccine industry and immunization program.
Background
Approximately 700 million vaccine doses are produced annually in China, making China one of the world's largest producers of vaccines [1, 2] . China's National Regulatory system for vaccines passed assessments by the World Health Organization (WHO) in 2011 and 2014, indicating that China's vaccine regulatory oversight meets WHO/international standards [1] . Vaccines are made available through the government's Expanded Program on Immunization (EPI) at no charge for all children up to 14 years of age [3] . These government-purchased vaccines are called Category 1 vaccines under the Regulations on the Administration of Vaccine and Vaccination. In contrast, private-sector (Category 2) vaccines, such as Haemophilus influenzae type b vaccine (Hib), rabies vaccine, and influenza vaccine (InfV), are available in China, but are usually paid for out-of-pocket, as they are included in neither the EPI system nor government health insurance.
China's vaccine industry and immunization program have some differences compared with other countries' industries and programs, but an overview of the Chinese vaccine industry and immunization effort has not been published in the international scientific literature. In order to allow international peers know better about the development of Chinese vaccine industry and immunization program and share experience, we analyzed selected aspects of vaccines and immunization in China and report the history, immunization policies, classification, supply, and price of vaccines in comparison with selected highand middle-income countries.
Methods

Vaccine supplied, expanded program of immunization and categorization
We obtained names of vaccines supplied in China between 1930s and 2016 from Applied Vaccination Handbook, the Biologicals Lot Release program of the National Institutes for Food and Drug Control (NIFDC), China Food and Drug Administration (CFDA) (http://www. nicpbp.org.cn/CL0001/). We determined official classification of vaccines into Category 1 or 2, and, when appropriate, year of integration into EPI from the documents, "Expanded National Immunization Program Planning and Implementation" by the National Health and Facility Planning Commission (NHFPC) (http://www.nhfpc.gov.cn) and "Applied Vaccination Handbook" [4] . We obtained year of licensure from CFDA (http://samr.cfda.gov.cn/ WS01/CL0001/) and from the document, "Applied Vaccination Handbook" [3] . We obtained immunization schedules from the Chinese Center for Disease Control and Prevention (China CDC) [5] and "Applied Vaccination Handbook" [4] .
We compared the list of vaccine of China with high-income countries including UK, US and middleincome countries including Brazil, Russia, India and South Africa. We obtained lists of vaccines available in the United States (US) and the United Kingdom (UK) from US CDC [6] and Public Health England [7] . Lists of vaccines and diseases prevented through routine immunization for China, US, UK, Brazil, Russia, India, and South Africa were obtained from China CDC, UNICEF, and WHO [8] .
Vaccine supply
We obtained the numbers of doses of vaccines released in China between 2007 and 2015 from NIFDC. Officially-classified Category 1 vaccines were: oral poliovirus vaccine (OPV), Group A meningococcal polysaccharide vaccine (MenA), Group A and C meningococcal polysaccharide vaccine (MenAC), hepatitis A live attenuated (HepA-L), hepatitis B vaccine (HepB), Bacillus Calmette-Guerin vaccine (BCG), diphtheriatetanus-pertussis whole cell vaccine (DTwP), diphtheriatetanus-pertussis acellular vaccine (DTaP), diphtheria and tetanus combined vaccine (DT), tetanus toxoid vaccine (TT), live attenuated Japanese encephalitis vaccine (JEV-L), inactivated Japanese encephalitis vaccine (JEV-I), measles-rubella vaccine (MR), measles, mumps combined vaccine (MM), measles-mumps-rubella vaccine (MMR), live attenuated measles vaccine (MV-L), mumps vaccine (Mumps), rubella vaccine (Rubella), hemorrhagic fever with renal syndrome (HFRS), leptospirosis vaccine (Leptospira), and anthrax vaccines (Anthrax). Pandemic H1N1 vaccine (H1N1) was classified as Category 1 because it was purchased by the government and made available at no cost to those vaccinated [9] . All other vaccines were Category 2, private-sector vaccines.
Prices
We obtained vaccine prices from the Chinese Central Government Procurement (CCGP) office and from vaccine contracts published in the E-procured system by departments of health or CDCs in central, provincial, autonomous regions, municipal, city, and county-level governments [10] . We used "NIP vaccine" and "Category 2 vaccine" as separate keywords to search for vaccine prices. For analyses, we used the lowest price for each vaccine, consistent with procurement practices. We compared procurement prices in China with those of US, Europe and low-income countries. Vaccine prices of US were obtained from US CDC Vaccine Price List [6] . Vaccine prices for European countries were collected from "Review of Vaccine Price Data, 2013" by WHO European [11] . A total of 24 European countries reported their procurement prices for 41 vaccines. The median price for each vaccine were used in the comparison. Many low-income countries can obtain vaccines at low prices from UNICEF; we therefore used vaccine price data published by UNICEF instead of that of lowincome countries [12] . The exchange rate for US dollars vs Chinese Yuan was 6.2. Cost data were collected between 2013 and 2015.
Results
Vaccine list
In China, 30 diseases are preventable by 50 vaccines (information on vaccine preventable diseases, vaccine categories, and years of EPI introduction are provided in Additional file 1: Figure S1 Although China produces almost all vaccines that are in common use globally, [2] compared with the US, the UK, and European countries, fewer vaccines are available in China. Meningococcal B (MenB) vaccine and adenovirus (Adenovirus) vaccine are not available in China (Additional file 1: Table S2 ). Human papillomavirus vaccine (HPV) was licensed in July 2016, ten years after licensure in some high-income countries. Multicomponent vaccines such as MMR-Varicella (MMRV), HepB-Haemophilus influenzae type b conjugate vaccine (Hib), Typhoid-HepA, DTaP-IPV/HepB, and DTaPHib/Hep/IPV are not available in China.
Expanded program of immunization
In the 1950s, only smallpox and BCG vaccines were used universally in China, while diphtheria, JEV, Cholera, and Plague, and TT vaccines were used for epidemic control. (Fig. 2) .
Nineteen different EPI vaccines existed in 2007, decreasing to 13 in 2015 through substitution with combination vaccines. Compared with high-income countries (HICs) such as the UK and the US, China's EPI system used more monovalent vaccines and lacked large combination vaccines like DTap-HepB/IPV and DTap-Hib/IPV (Additional file 1: Figure S1 ). Figure 3 depicts the national immunization program vaccines in high-income counties such as US and UK, middle income countries such as Russia, Brazil, India and South Africa. The National Immunization Program in China had more VPDs preventable by EPI vaccines than Russia, India and South Africa, but fewer VPDs preventable than the national programs in the US, UK and Brazil. Hib vaccine, pneumococcal conjugate vaccine (PCV) and rotavirus vaccine have been included in the US, UK, Brazil and South Africa' national immunization programs, while China's EPI has included none of these vaccines (Fig. 3) . Hib vaccine, PCV13, oral rotavirus vaccine (ORV), varicella vaccine (Var), and seasonal influenza vaccine (InfV) were available only as Category 2 vaccines in China, while meningococcal group B (MenB) vaccine was not available in China. 
Category 2 (private-sector) vaccines are considered non-obligatory and must be paid for by the parent or person vaccinated. Rabies vaccine is a Category 2 vaccine even though its use in post-exposure prophylaxis following a bite from a rabid animal cannot be considered non-obligatory. Prior to April 2016, manufacturers were allowed to sell Category 2 vaccines to wholesalers, county or district CDCs, and vaccination clinics and other healthcare providers. In 2016, the Chinese government revised the legal framework for vaccines and immunization ("Vaccine Distribution and Vaccination Regulations") in partial response to an illegal Category 2 vaccine sales ring based in Shandong province in 2016 [15] . The updated law specified that all Category 2 vaccines must be procured using government procurement platforms, [16] essentially requiring Category 2 vaccines to be managed by the system that manages Category 1 vaccines. The updated law bans vaccine sales through the Internet and wholesalers, instead directing all distribution through CDCs. In January 2017, the Chinese State Council again updated the Vaccine Circulation and Immunization regulation. The update requested establishment of a national advisory committee of experts to make recommendations for inclusion of vaccines into the EPI system based on vaccine safety, effectiveness, cost-effectiveness, and production capacity and to update recommendations on existing EPI vaccines. The update also encouraged new vaccine innovation through national science projects.
Vaccine supply
From 2007 to 2015, 55 vaccines were licensed in China; 48 (78%) were manufactured domestically. The number of manufacturers for each vaccine varies from 1 (for TBE vaccine) to 21 (for InfV) (Additional file 1: Table  S1 ). Most of the vaccines manufactured in China were used domestically. Three vaccines (JEV-L made by Chengdu Institute of Biological Products; InfV, made by Hualan Biological; and inactivated hepatitis A vaccine, made by Sinovac Biotech Co. Ltd.) have been prequalified by WHO, [1, 16] enabling procurement by UNICEF and Gavi for use in other countries. Figure 4 shows the number of vaccine doses distributed by year, broken down by category and location of production (domestic or international). Between 2007 and 2015, the supply volume varied from 666 million doses to 1.19 billion doses, with Category 1 vaccines accounting for the majority of vaccines supplied. Virtually all Category 1 vaccines were produced domestically, as were approximately 80% to 90% of Category 2 vaccines. Variation in the supply of Category 1 vaccine reflects national campaigns with H1N1 vaccine, HepB vaccine, and monovalent MV-L vaccine [9, 17, 18] .
Price
In China, both Category 1 and Category 2 vaccines are procured by government using a centralized platform. Category 1 vaccines are provided free of charge, while Category 2 vaccines are paid for out-of-pocket by the family. Figure 5 shows vaccine procurement prices in China, US, European countries, and UNICEF. The price range for Category 1 vaccines was $0.1-5.7 USD, and the price range for Category 2 vaccines was $2.4-102.9 USD. Procurement prices of EPI-substitute vaccines (Category 2 vaccines against diseases preventable by Category 1 vaccines) were higher than for their EPI equivalents.
Category 1 vaccine prices were lower than for the same vaccines in the US and European countries, but were similar to UNICEF prices. Prices of domestically-produced Category 2 vaccines, such as seasonal influenza, Hib, Var, and ORV, were lower than prices of similar vaccines in the US, Europe, and UNICEF. PCV7 and DTaP-IPV/Hib were higher in price than similar vaccines in the US, Europe and UNICEF (Fig. 5) .
Discussion
Despite significant achievements in vaccine development and production, and the attainment of important goals for polio eradication, hepatitis B control, and tetanus elimination in the past two decades, China's EPI system protects children from fewer diseases than many high-income and middle-income countries. Notable is the lack Hib, ORV, PCV, influenza and HPV vaccines in China's EPI system -vaccines that are recommended by WHO for all countries' national immunization programs but are available only as private-sector vaccines in China.
China's immunization program has made very good use of the EPI vaccines. Polio was eradicated by 2000; [19] the prevalence of chronic hepatitis B infection has been reduced by 97% among young children compared with the pre-vaccine era; [17] the annual incidence of measles has been reduced by more than 99% [18] . Strategic use of effective vaccines made these achievements possible, despite the challenges of a large population and a vast territory with many densely-populated areas. There are several experiences that could be helpful in low-income countries: 1) China has a large domestic manufacturing base capable of producing large quantity of vaccines at low prices, which has enabled all eligible children to be vaccinated free of charge; 2) the Chinese government has encouraged through policy development expansion of the number of diseases preventable by vaccines; and 3) stringent requirements ensuring access to vaccines through thousands of CDCs and over 200,000 vaccination clinics have ensured high coverage of EPI vaccines. We believe that China's immunization program experience can help other countries achieve similar results with effective, inexpensive vaccines.
In industrialized countries like the US and the UK, almost all vaccines are regarded as "public goods," ensuring their availability for all children [20, 21] . However, some vaccines that WHO recommends for all national immunization programs are Category 2 vaccines in China, which require out-of-pocket payment by parents or persons vaccinated. Category 2 vaccines are associated with lower coverage levels and with coverage that varies by wealth of province. For example, coverage with ORV is 23.7%, and coverage with Hib vaccine is 45.3%. China ranks 7th highest in the world for VPD burden, indicating that more complete implementation of underutilized vaccines can contribute to a healthier childhood population [22] .
The fluctuation of vaccine supply in 2007-2015 shows that the vaccine demand depends on the birth cohort and the government-oriented catch up campaigns. In 2015, the amendment of "Population and Family Planning Law of" was changed China's one-child policy to a two-child policy. This change will lead to an increase in the birth cohort size and to an increase in vaccine demand.
The prices of China's Category 1 vaccines were much lower than high-income country and some UNICEF vaccine prices. Low vaccine prices may provide manufacturers with less incentive to invest in production improvements and new vaccine development, which may be a partial explanation for the lack of domestic production of large combination vaccines. From a short-to medium-term public health perspective, lower-cost vaccines are preferable because more children can be vaccinated for a given budget [23] . Low pricing can be achieved in part through large demands in an economy of scale [24] . Prices for Category 2 vaccines may be high because their demand volumes are not large enough to achieve an economy of scale. Manufacturers of Category 2 vaccines profit from high prices, which provides an incentive to stay in the market and fund innovations in research and development of novel vaccines. Finding a balance between manufacturers' profit needs and public health's needs is challenging. The 2-category system in China is one approach to finding a balance, with traditional vaccines in the program and newer vaccines available in China, but not provided by the program.
Our study has limitations and strengths. Limitations include (1) that procurement prices can vary by province, and we were not able to capture that variation in the study, and (2) that CFDA lot-release program data were not available prior to 2007 [1] . A strength is that we used official government-reported vaccine licensure information, dose amounts, and pricing. For example, CFDA's lot-release program was the source of information on the number of doses available in China, and government procurement offices were the source for price information.
Conclusions
We believe that our study supports two recommendations. First 
